Purpose: To evaluate the effect of using fluoxetine at different time intervals after ischemic stroke on neurological functional prognosis in China.
Methods: The patients enrolled were randomly allocated to three groups. Group A received fluoxetine 20 mg/day immediately; group B received fluoxetine 20 mg/day 7 days after enrollment; and group C did not receive fluoxetine. The therapeutic duration of fluoxetine was 90 days and the follow-up period was 180 days.
Results: The mean NIHSS score at day 90 was significantly lower in group A than group C (P = 0.005), while at day 180, the mean score in group A was significantly lower than groups B and C (P = 0.035, P = 0.000), respectively. The mean BI score at day 90 was significantly higher in group A than group C (P = 0.001), while at day 180, the mean score in group A was significantly higher than groups B and C (P = 0.036, P = 0.000), respectively. Regression analysis indicated that lower NIHSS score and higher BI score at day 180 were attributed to the early administration of fluoxetine.
Conclusions: In patients with ischemic stroke, early administration of fluoxetine may improve the neurological functional prognosis.
AclerM., RobolE., FiaschiA., ManganottiP. (2009). A double blind placebo RCT to investigate the effects of serotonergic modulation on brain excitability and motor recovery in stroke patients. Journal of Neurology, 256, 1152–1158.
2.
AhmedN., NäsmanP., WahlgrenN.G. (2000). Effect of intravenous nimodipine on blood pressure and outcome after acute stroke. Stroke, 31, 1250–1255.
3.
CholletF., TardyJ., AlbucherJ.F., ThalamasC., BerardE., LamyC., BejotY., DeltourS., JaillardA., NiclotP., GuillonB., MoulinT., MarqueP., ParienteJ., ArnaudC., LoubinouxI. (2011). Fluoxetine for motor recovery after acute ischaemic stroke (FLAME): A randomised placebo-controlled trial. The Lancet Neurology, 10, 123–130.
4.
Chotik-anuchitS., NilanontY., PoungvarinN. (2011). Relationship between ankle brachial index (ABI), high sensitivity C-reactive protein (hs-CRP) and initial disability level in acute ischemic stroke. Journal of the Medical Association ofThailand, 94, S94–S98.
5.
De FoubertG., CarneyS.L., RobinsonC.S., DestexheE.J., TomlinsonR., HicksC.A., MurrayT.K., GaillardJ.P., DevilleC., XhensevalV., ThomasC.E., O’NeillM.J., ZetterströmT.S. (2004). Fluoxetine-induced change in rat brain expression of brain-derived neurotrophic factor varies depending on length of treatment. Neuroscience, 128, 597–604.
6.
DhamiK.S., ChurchwardM.A., BakerG.B., ToddK.G. (2013). Fluoxetine and citalopram decrease microglial release of glutamate and D-serine to promote cortical neuronal viability following ischemic insult. Molecular and Cellular Neurosciences, 56, 365–374.
7.
DirnaglU., IadecolaC., MoskowitzM.A. (1999). Pathobiology of ischaemic stroke: An integrated view. Trends in Neurosciences, 22, 391–397.
FurieK.L., KasnerS.E., AdamsR.J., AlbersG.W., BushR.L., FaganS.C., HalperinJ.L., JohnstonS.C., KatzanI., KernanW.N., MitchellP.H., OvbiageleB., PaleschY.Y., SaccoR.L., SchwammL.H., Wassertheil-SmollerS., TuranT.N., WentworthD., American Heart Association, Council on Cardiovascular Nursing, Council on Clinical Cardiology, Interdisciplinary Council on Quality of Care, Outcomes, Research, (2011). Guidelines for the Prevention of Stroke in Patients With Stroke or Transient Ischemic Attack: A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association. Stroke, 42, 227–276.
10.
GandhiS., AbramovA.Y. (2012). Mechanism of oxidative stress in neurodegeneration. Oxidative Medicine and Cellular Longevity, 2012, 428010.
11.
GaurV., KumarA. (2010). Behavioral, biochemical and cellular correlates in the protective effect of sertraline against transient global ischemia induced behoral despair: Possible involvement of nitric oxide-cyclic guanosine monophosphate study pathway. Brain Research Bulletin, 82, 57–64.
12.
GreeneJ., BanasrM., LeeB., Warner-SchmidtJ., DumanR.S. (2009). Vascular endothelial growth factor signaling is required for the behavioral actions of antidepressant treatment: Pharmacological and cellularcharacterization. Neuropsychopharmacology, 34, 2459–2468.
13.
HsuehI.P., LinJ.H., JengJ.S., HsiehC.L. (2002). Comparison of the psychometric characteristics of the functional independence measure, 5 item Barthel index, and 10 item Barthel index in patients with stroke. Journal of Neurology, Neurosurgery, Psychiatry, 73, 188–190.
14.
JinK., WangX., XieL., MaoX.O., ZhuW., WangY., ShenJ., MaoY., BanwaitS., GreenbergD.A. (2006). Evidence for stroke-induced neurogenesis in the human brain. Proceedings of the National Academy of Sciences of the United States of America, 103, 13198–13202.
15.
KarpovaN.N., PickenhagenA., LindholmJ., TiraboschiE., KulesskayaN., AgústsdóttirA., AntilaH., PopovaD., AkamineY., BahiA., SullivanR., HenR., DrewL.J., CastrénE. (2011). Fear erasure in mice requires synergy between antidepressant drugs and extinction training. Science, 334, 1731–1734.
Kim doH., LiH., YooK.Y., LeeB.H., HwangI.K., WonM.H. (2007). Effects of fluoxetine on ischemic cells and expressions in BDNF and some antioxidants in the gerbil hippocampal CA1 region induced by transient ischemia. Experimental Neurology, 204, 748–758.
18.
KochanekP.M., DutkaA.J., HallenbeckJ.M. (1987). Indomethacin, prostacyclin, and heparin improve postischemic cerebral blood flow without affecting early postischemic granulocyte accumulation. Stroke, 18, 634–637.
19.
KuberaM., GrygierB., ArtetaB., UrbańskaK., Basta-KaimA., BudziszewskaB., LeśkiewiczM., KołaczkowskaE., MaesM., SzczepanikM., MajewskaM., LasońW. (2009). Age-dependent stimulatory effect of desipramine and fluoxetine pretreatment on metastasis formation by B16F10 melanoma in male C57BL/6 mice. Pharmacological Reports, 61, 1113–1126.
20.
KunitzS.C., GrossC.R., HeymanA., KaseC.S., MohrJ.P., PriceT.R., WolfP.A. (1984). The pilot Stroke Data Bank: Definition, design, and data. Stroke, 15, 740–746.
21.
LeeJ.S., JangD.J., LeeN., KoH.G., KimH., KimY.S., KimB., SonJ., KimS.H., ChungH., LeeM.Y., KimW.R., SunW., ZhuoM., AbelT., KaangB.K., SonH. (2009). Induction of neuronal vascular endothelial growth factor expression by cAMP in the dentate gyrus of the hippocampus is required for antidepressant-like behaviors. The Journal of Neuroscience, 29, 8493–8505.
22.
LimC.M., KimS.W., ParkJ.Y., KimC., YoonS.H., LeeJ.K. (2009). Fluoxetine affords robust neuroprotection in the postischemic brain via its anti-inflammatory effect. Journal of Neuroscience Research, 87, 1037–1045.
23.
LiuX., ZhangJ., SunD., FanY., ZhouH., FuB. (2014). Effects of fluoxetine on brain-derived neurotrophic factor serum concentration and cognition in patients with vascular dementia. Clinical Interventions in Aging, 9, 411–418.
24.
LiW.L., CaiH.H., WangB., ChenL., ZhouQ.G., LuoC.X., LiuN., DingX.S., ZhuD.Y. (2009). Chronic fluoxetine treatment improvesi schemia-induced spatial cognitive deficits through increasing hippocampal neurogenesis after stroke. Journal of Neuroscience Research, 87, 112–122.
25.
Martí-FábregasJ., Romaguera-RosM., Gómez-PinedoU., Martínez-RamírezS., Jiménez-XarriéE., MarínR., Martí-VilaltaJ.L., García-VerdugoJ.M. (2010). Proliferation in the human ipsilateral subventricular zone after ischemic stroke. Neurology, 74, 357–365.
26.
MiniñoA.M., MurphyS.L., XuJ., KochanekK.D. (2011). Deaths: Final data for 2008. National Vital Statistics Reports, 59, 1–126.
27.
ParienteJ., LoubinouxI., CarelC., AlbucherJ.F., LegerA., ManelfeC., RascolO., CholletF. (2001). Fluoxetine modulates motor performance and cerebral activation of patients recovering from stroke. Annals of Neurology, 50, 718–729.
28.
PROGRESS Collaborative Group. (2001). Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack. Lancet, 358, 1033–1041.
29.
SnyderJ.S., ChoeJ.S., CliffordM.A., JeurlingS.I., HurleyP., BrownA., KamhiJ.F., CameronH.A. (2009). Adult-born hippocampal neurons are more numerous, faster maturing, and more involved in behavior in rats than in mice. The Journal of Neuroscience, 29, 14484–14495.
30.
SmithC.J., EmsleyH.C., GavinC.M., GeorgiouR.F., VailA., BarberanE.M., del ZoppoG.J., HallenbeckJ.M., RothwellN.J., HopkinsS.J., TyrrellP.J. (2004). Peak plasma interleukin-6 and other peripheral markers of inflammation in the first week of ischaemic stroke correlate with brain infarct volume, stroke severity and long-term outcome. BMC Neurology, 4, 2.
31.
TilleyB.C., MarlerJ., GellerN.L., LuM., LeglerJ., BrottT., LydenP., GrottaJ. (1996). Use of a global test for multiple outcomes in stroke trials with application to the National Institute of Neurological Disorders and Stroke t-PA Stroke Trial. Stroke, 27, 2136–2142.
32.
UyttenboogaartM., StewartR.E., VroomenP.C., De KeyserJ., LuijckxG.J. (2005). Optimizing cutoff scores for the Barthel index and the modified Rankin scale for defining outcome in acute stroke trials. Stroke, 36, 1984–1987.
33.
VautheyC., de FreitasG.R., van MelleG., DevuystG., BogousslavskyJ. (2000). Better outcome after stroke with higher serum cholesterol levels. Neurology, 54, 1941–1942.
34.
VemmosK.N., TsivgoulisG., SpengosK., ZakopoulosN., SynetosA., ManiosE., KonstantopoulouP., MavrikakisM. (2004). U-shaped relationship between mortality and admission blood pressure in patients with acute stroke. Journal of Internal Medicine, 255, 257–265.
ZhangT., WangC., LiuL., ZhaoX., XueJ., ZhouY., WangY., WangY. (2010). A prospective cohort study of the incidence and determinants of post-stroke depression among the mainland Chinese patients. Neurological Research, 32, 347–352.
37.
ZittelS., WeillerC., LiepertJ. (2008). Citalopram improves dexterity in chronic stroke patients. Neurorehabilitation and Neural Repair, 22, 311–314.
